InNexus Biotechnology Announces an Expansion of its SuperAntibody R&D Program
Advertisement
InNexus Biotechnology Inc. announced the extension and expansion of its research and development program for SuperAntibody Technology (SAT) by expanding its R&D facilities within the Kentucky Technology Center on the Coldstream Research Campus in Lexington, Kentucky. This modern laboratory facility includes equipment for fluorescence flow cytometry analysis (FACS), ELISA, a full protein chemistry lab, cell culturing and other infrastructure.
The expansion is being made to accommodate more partnerships, expanded R&D activities, and scale-up of its product development program to advance development of InNexus' leading drug candidate, SuperAntibody(TM) T15, a treatment for reduction of plaque in coronary artery disease. InNexus is focused on maximizing the value of its two technology platforms, SuperAntibody(TM) and TranMAbs(TM), for empowering monoclonal antibodies.
Commenting on the announcement, Dr. Charles Morgan, the President of InNexus, said: "This expansion further validates our commitment to our partners for providing resources and capacity for SuperAntibody development. Interest in our SAT platform has outstripped our previous resources and the new facility increases our ability to enter into partnerships by increasing our ability to provide R&D feasibility studies and generate the data required for the development projects of our partners".